Glow-in-the-Dark drug could help surgeons spot brain cancer
NCT ID NCT07210632
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early-phase trial tests a special version of the immunotherapy drug nivolumab that has a fluorescent dye attached (nivo800). The dye makes the drug glow under near-infrared light, allowing researchers to see exactly where the drug goes in the tumor during surgery. About 38 adults with suspected high-grade glioma will receive a single infusion before their planned tumor removal. The main goal is to check safety and find the best dose for imaging, not to treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab-IRDye800 (nivo800)
What this could lead to
If successful, this could improve surgeons' ability to see tumor tissue during operations, potentially leading to more complete removal of high-grade gliomas.
What could go wrong
This is a very early, small safety and imaging study (38 participants). It is not designed to test whether the drug treats the tumor, and the imaging benefit may not translate into better outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.